On July 15, Novo Nordisk rose 3.07% in regular trading, trading at $50.515/share, with turnover of $116 million. The rally was driven by newly released prescription data confirming the company's dominant position in the oral weight-loss drug category.
IQVIA data for the week ending July 3 showed that Wegovy oral formulation captured approximately 153,100 US prescriptions, compared to just 19,600 for Eli Lilly's Foundayo — giving Novo Nordisk 89% of the oral GLP-1 weight-loss prescription market versus Lilly's 11%. By week 13 after launch, Wegovy oral prescriptions exceeded 105,000 per week, more than five times Foundayo's volume over the same post-launch period. Analysts have since cut Foundayo sales forecasts, while Eli Lilly noted that physician and patient awareness would gradually build momentum for its product.
The data reinforces Novo Nordisk's first-mover advantage in oral obesity treatments, a segment Goldman Sachs projects could reach $46 billion by 2030. The competitive gap is also reflected in sector performance, with Eli Lilly declining 1.07% during the same session.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
